(Q34187883)

31 July 2017

1 reference

title

The use of chromatography to manufacture purer and safer plasma products (English)

1 reference

31 July 2017

Johnston A

1

1 reference

31 July 2017

Adcock W

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2000

1 reference

Biotechnology and Genetic Engineering Reviews

31 July 2017

published in

1 reference

31 July 2017

volume

17

1 reference

31 July 2017

page(s)

37-70

1 reference

Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Chromatography in plasma fractionation: benefits and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Biochemical and physical properties of a solvent-detergent-treated fibrin glue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Acquired immunodeficiency syndrome (AIDS) associated with transfusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Large-Scale Gel Filtration Chromatography for the Production of a Solvent/Detergent-Treated High-Purity Factor VIII Concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Active respiratory syncytial virus purified by ion-exchange chromatography: characterization of binding and elution requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Purification of Hepatitis B Surface Antigen by Affinity Chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Plasma derivatives and viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Acute hepatitis A in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Isolation and characterization of alpha-1-antitrypsin from the Cohn fraction IV-I of human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Purification of bovine papilloma virus by gel filtration on Sephacryl S-1000 superfine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Purification and large-scale preparation of antithrombin III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Prevention of Rh-immunization. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Effects of exposure to factor concentrates containing donations from identified AIDS patients. A matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Non-A, non-B hepatitis from intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Inactivation of hepatitis C virus in low pH intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Outbreak of hepatitis A among Italian patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

A Therapeutic Concentrate of Coagulation Factors II, IX and X from Citrated, Factor VIII-Depleted Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Hepatitis A virus PCR analysis of clotting factor concentrates and elimination of non-enveloped viruses in their manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Acute hepatitis A in patients with haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Chromatography of Proteins. I. Cellulose Ion-exchange Adsorbents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Gel filtration: a method for desalting and group separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Metal chelate affinity chromatography, a new approach to protein fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Human parvovirus B19 and blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Virological safety of the purified factor IX concentrate, Replenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Virus Safety of Plasma Products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Removal of parvovirus and hepatitis A virus by metal chelate affinity chromatography during the preparation of Replenine: a high-purity factor IX concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Augmented tumour necrosis factor in Reye's syndrome associated with dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Purification of the factor VIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Selective removal of albumin from plasma by affinity chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Development of large scale fractionation methods. VII. Preparation of antithrombin III concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

Chronic hepatitis C after high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02648725.2000.10647987

10.1080/02648725.2000.10647987

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference